Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0TBCEQ
ADC Name	HS-20093
Synonyms	HS20093; HS 20093 Click to Show/Hide
Organization	Shanghai Hansoh Biomedical Co. Ltd.
Drug Status	Phase 2
Indication	In total 2 Indication(s) Osteosarcoma [ICD11:2B51] Phase 2 Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 1
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	CD276 antigen (CD276)		Antigen Info
Payload Name	Undisclosed
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT05276609	Phase 1	ARTEMIS-001: A phase 1, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and efficacy of multiple doses of intravenous administration of HS-20093 in patients with locally advanced or metastatic solid tumors who have progressed following prior therapy. Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
*Related Clinical Trial*
NCT Number	NCT05276609	Clinical Status	Phase 1
Clinical Description	ARTEMIS-001: A phase 1, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and efficacy of multiple doses of intravenous administration of HS-20093 in patients with locally advanced or metastatic solid tumors who have progressed following prior therapy.

References

Ref 1	ARTEMIS-001: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Intravenous Administration of HS-20093 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy, NCT05276609